论文部分内容阅读
目的通过对比化疗前乳腺癌组织和化疗后残存乳腺癌组织中乳腺癌耐药蛋白(ABCG2)、P-糖蛋白(P-gp)表达差异,探讨其与乳腺癌干细胞(BCSCs)的相关性。方法免疫组织化学检测化疗前乳腺癌组织和化疗后残存乳腺癌组织ABCG2、P-gp及BCSCs标志物CD44及CD24蛋白的表达;免疫荧光检测“BCSCs微球体”细胞中CD44及CD24蛋白表达;有限稀释法检测“BCSCs微球体”细胞单克隆形成能力;Western blot检测“BCSCs微球体”细胞ABCG2、P-gp、CD44及CD24蛋白的表达。结果与化疗前乳腺癌组织相比,化疗后残存乳腺癌组织ABCG2、P-gp表达与CD44蛋白表达呈正相关(χ2=41.34,r=0.83;χ2=22.81,r=0.61);而其与CD24蛋白表达呈负相关(χ2=-21.25,r=0.72;χ2=-17.26,r=0.65);差异均有统计学意义(P<0.05)。化疗后残存乳腺癌组织中“BCSCs微球体”直径明显增加,且化疗后BCSCs含量是化疗前BCSCs含量的2.5倍;Western blot显示化疗后残存乳腺癌组织“BCSCs微球体”细胞ABCG2、P-gp及CD44蛋白表达明显升高(P<0.05),而CD24蛋白表达明显降低(P<0.05)。结论化疗赋予残存乳腺癌组织“癌干细胞样”特征,导致乳腺癌多药耐药产生。
Objective To compare the expression of ABCG2 and P-glycoprotein (P-gp) in breast cancer tissues before and after chemotherapy, and to explore its relationship with breast cancer stem cells (BCSCs). Methods Immunohistochemistry was used to detect the expressions of CD44 and CD24 on ABCG2, P-gp and BCSCs in breast cancer tissues before and after chemotherapy. Immunofluorescence was used to detect the expression of CD44 and CD24 on “BCSCs microspheres” The expression of ABCG2, P-gp, CD44 and CD24 in “BCSCs microspheres” cells were detected by limited dilution method and “BCSCs microspheres” cell monoclonal antibody. Results The expression of ABCG2 and P-gp in residual breast cancer tissue was positively correlated with the expression of CD44 protein after chemotherapy (χ2 = 41.34, r = 0.83; χ2 = 22.81, r = 0.61) The protein expression was negatively correlated (χ2 = -21.25, r = 0.72; χ2 = -17.26, r = 0.65). The differences were statistically significant (P <0.05). After chemotherapy, the number of BCSCs microspheres significantly increased in residual breast cancer tissue after chemotherapy, and the content of BCSCs after chemotherapy was 2.5 times that of BCSCs before chemotherapy. The expression of BCSCs in BCSCs was significantly higher than that in BCSCs , P-gp and CD44 protein expression was significantly increased (P <0.05), while CD24 protein expression was significantly reduced (P <0.05). Conclusions Chemotherapy conferred residual breast cancer tissue characteristics of “cancer stem cells like”, leading to multidrug resistance of breast cancer.